Nadine Blaney

Yeah, I think it's been a bit of a sad tale over the past four years.

Think back to 2020.

CSL was the largest company on the ASX.

Now, obviously, that was ultimately overtaken by CBA.

But...

You know, its troubles, you could say, really began around August 2022.

And that's when it bought the aforementioned Swiss-based Vifor Pharma for $19 billion.

So Vifor is a company with treatments for iron deficiency, dialysis, and nephrology.

The business initially struggled under CSL's ownership, and I guess, Sean, ultimately, it's just not given CSL the boost it hoped for, and hence that massive write-down yesterday.

Yeah, and I never thought that I'd be on air, on Ausbiz, speaking with our expert guests, questioning whether CSL represents value or whether it's a value trap, you know.

And when you consider that the share price was above $300 not that long ago and yesterday falling below that $100 level, it's extraordinary.

Yeah.

Well, it contributed to the problems on the S&P ASX 200 yesterday.

It fell by about half a percent.

Hopes of a peace deal between the U.S.

and Iran were dashed by the U.S.

President Donald Trump.

He called a proposal from Iran to end the conflict totally, and this is a quote, unacceptable.

We will see.

And we will see what happens with this budget.